Medicamen Organics Limited IPO: What Investors need to know?
Company Overview
Medicamen Organics Limited, established in 1995 and headquartered in New Delhi, is a pharmaceutical company that manufactures and markets a broad range of pharmaceutical formulations, including tablets, capsules, syrups, ointments, and more. The company is renowned for its quality products and commitment to innovation.
Promoter: Mr. Bal Kishan Gupta
Registered Office:
10 Community Centre No 2, Ashok Vihar Phase II, New Delhi, Delhi, 110052, India
Company Secretary & Compliance Officer: Ms. Varsha Bansal
Chief Financial Officer: Mr. Lalit Gupta
Docs: Medicamen DRHP
Medicamen Organics IPO Details
Issue Type |
100% Book Built Issue IPO |
Fresh Issue Size |
Up to 32,00,000 Equity Shares |
Face Value |
₹10 per Equity Share |
Price Band |
₹32 to ₹34 per share |
Lot Size |
4000 Shares |
Total Issue Size |
3,100,000 shares |
Fresh issue |
3,100,000 shares |
Listing |
Proposed on NSE Emerge |
Lead Manager |
GYR Capital Advisors Private Limited |
Registrar |
KFIN Technologies Limited |
IPO Important Dates
Event |
Date |
IPO Open Date |
Friday, June 21, 2024 |
IPO Close Date |
Tuesday, June 25, 2024 |
Basis of Allotment |
Wednesday, June 26, 2024 |
Initiation of Refunds |
Thursday, June 27, 2024 |
Credit of Shares to Demat |
Thursday, June 27, 2024 |
Listing Date |
Friday, June 28, 2024 |
Cut-off time for UPI mandate confirmation |
5 PM on June 25, 2024 |
Medicamen Organics Limited Financial Performance
Period Ended |
31 Mar 2024 |
31 Mar 2023 |
31 Mar 2022 |
31 Mar 2021 |
Assets |
3,858.07 |
3,211.98 |
2,707.21 |
2,634.37 |
Revenue |
2,528.96 |
2,296.24 |
2,118.67 |
2,505.96 |
Profit After Tax |
240.41 |
95.78 |
9.23 |
29.81 |
Net Worth |
1,518.40 |
851.71 |
755.92 |
746.72 |
Reserves and Surplus |
658.40 |
251.71 |
155.92 |
146.72 |
Total Borrowing |
1,265.65 |
1,179.50 |
1,024.57 |
958.97 |
Amount in ₹ Lakhs
Objectives of the IPO
- Expansion of manufacturing facilities.
- Investment in research and development.
- Repayment of certain borrowings.
- General corporate purposes.
Industry Overview
The Indian pharmaceutical industry is one of the largest globally, with significant contributions to generic drug production. The sector is poised for substantial growth due to increasing healthcare awareness, an aging population, and favorable government policies. Medicamen Organics Limited, with its strong market presence and diverse product portfolio, is well-positioned to capitalize on these opportunities.
Key Strengths
- Strong Market Presence: Established brand with a robust distribution network.
- Diverse Product Portfolio: Wide range of pharmaceutical formulations catering to various therapeutic segments.
- Commitment to Quality: Adherence to stringent quality standards and regulatory compliances.
- Experienced Management: Led by a team of seasoned professionals with extensive industry knowledge.
Risks
- Market Risks: The pharmaceutical market is highly competitive, and changes in market dynamics can impact the company’s performance.
- Regulatory Risks: The industry is subject to stringent regulations, and changes can affect operations.
- Operational Risks: Any disruption in manufacturing or supply chain can hinder the company’s ability to meet market demand.
Medicamen Organics Limited IPO Subscription Details
Category |
Subscription (times) |
Shares Offered |
Shares bid for |
QIB |
173.03 |
5,84,000 |
0 |
NII* |
1,343.83 |
4,40,000 |
20,12,000 |
Retail |
1,309.77 |
10,28,000 |
1,04,28,000 |
Total |
993.56 |
20,52,000 |
1,24,40,000 |
Grey Market Premium (GMP) Live Rates
Date |
IPO GMP |
Kostak |
Subject to |
Today |
₹50 |
₹- |
₹140,000 |
25 June |
₹50 |
|
₹140,000 |
24 June |
₹60 |
₹- |
₹170,000 |
21 June |
₹60 |
₹- |
₹170,000 |
19 June |
₹60 |
₹- |
₹170,000 |
18 June |
₹60 |
₹- |
₹170,000 |
17 June |
₹50 |
₹- |
₹150,000 |
14 June |
₹5 |
₹- |
₹10,000 |
Conclusion
The Medicamen Organics Limited IPO presents a promising investment opportunity, backed by the company’s strong financial performance, strategic expansion plans, and established market presence. However, potential investors should carefully evaluate the associated risks and perform thorough due diligence before investing.
Disclaimer: This review is based on information available from the Draft Red Herring Prospectus (DRHP) dated February 21, 2024. Investors are advised to read the risk factors carefully and perform their own analysis before making investment decisions.
For more information, visit Medicamen Organics Limited.
SEO Headlines
- Medicamen Organics Limited IPO: Detailed Review, Financials, and Subscription Status
- Everything You Need to Know About Medicamen Organics Limited IPO
- Medicamen Organics Limited IPO Subscription Status and GMP Live Rates
- Medicamen Organics Limited IPO: Financial Performance and Key Objectives
- Medicamen Organics Limited IPO: Is It Worth Investing? Detailed Analysis and Review